Seven separate lawsuits are now moving through court against Novo Nordisk and Eli Lilly, all touching on how GLP-1 drugs are priced and marketed. Most of the court records remain sealed, so the specific claims are not yet public. Still, if you take semaglutide or tirzepatide, these cases could eventually shape what you pay and what the drug ads tell you. None of the lawsuits has reached a settlement or ruling yet, but they are worth tracking as they develop.
One lawsuit against Novo Nordisk, identified in court records as Adkins v. Novo Nordisk Inc., is moving through the legal process and focuses on how the company prices and markets its GLP-1 drugs. The court filing does not yet reveal the specific allegations, since the record remains sealed. What matters for patients is the potential outcome: if the case proceeds and reaches a settlement or a court ruling, it could affect the price you pay for these medications at the pharmacy counter. Pricing lawsuits like this can take months or years to resolve, so any change would not happen right away. For now, the case is one to watch rather than one that changes anything today.
A separate case, Fernandez v. Eli Lilly and Company, claims the company broke rules in how it marketed its GLP-1 drugs. The lawsuit is still working its way through court, and the specific marketing claims at issue have not been made public yet. If the case moves forward, it could end in a settlement between Lilly and the plaintiffs, or it could lead to changes in how the drug is marketed or labeled going forward. Either outcome would matter to anyone who relies on drug advertising or packaging to understand what a medication does. Right now, though, the case remains in an early stage, and no resolution has been reached.
Novo Nordisk faces another lawsuit, Michaelis v. Novo Nordisk A/S, that also challenges the company's pricing and marketing of its GLP-1 drugs, separate from the Adkins case described above. The substance of the claims in this filing is not yet public, but cases built around pricing and marketing practices can end in a few different ways. A settlement between the company and the plaintiffs is one possibility. A change to the drug's label, meant to correct or clarify information for patients and prescribers, is another. Because two lawsuits with similar themes are proceeding against the same company at once, the outcome of one may offer some indication of how the other could unfold.
Eli Lilly is also facing a lawsuit, Garner v. Eli Lilly and Company, over how it has marketed its GLP-1 drugs. Like several of the other cases, the record here is sealed, so the specific marketing practices being challenged are not yet known. The case is pending in court, which means it has not reached a resolution and could take time before more information becomes available. Patients who use Lilly's GLP-1 products may want to keep an eye on this case alongside the Fernandez case, since both concern marketing rather than pricing. As with the other lawsuits, no settlement or ruling has been reached yet.
The most recently filed case, McKenzie v. Novo Nordisk Inc., specifically names semaglutide, the active ingredient in some of Novo Nordisk's GLP-1 drugs, as the focus of its pricing and marketing claims. Because this lawsuit is newer than the others, it is even earlier in the legal process, and the underlying allegations have not been made public. Naming the specific drug ingredient, rather than referring to the company's GLP-1 products more broadly, may suggest the claims focus on how semaglutide in particular has been priced or advertised. It is too soon to know what this case will mean for patients who take semaglutide-based medications. For now, it joins the other Novo Nordisk suits as one more filing to track as details emerge.
If you currently take a GLP-1 medication from either company, these lawsuits are not a reason to change your treatment on your own. Court records remain sealed, and none of the cases has produced a settlement, ruling, or label change so far. I would suggest checking back on these cases periodically, since sealed records tend to open up as litigation proceeds, and following any official announcements from Novo Nordisk or Eli Lilly about their products. If you have questions about the cost or marketing of a specific drug in the meantime, your pharmacist or insurance provider can offer more immediate answers than a lawsuit still working through the courts.
Key details
Novo Nordisk faces a lawsuit that could affect what patients pay for GLP-1 drugs.
A lawsuit claims Eli Lilly broke GLP-1 marketing rules, which could bring settlements.
A separate case against Novo Nordisk could also lead to settlements or label changes.
Eli Lilly faces another lawsuit over its GLP-1 marketing practices, pending in court.
A newer lawsuit against Novo Nordisk targets its pricing and marketing of semaglutide.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-08-27